Sanofi India Ltd

For the third consecutive session, Sanofi India Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 3,270 on 23 Mar 2026. This marks a significant 51.3% drop from its 52-week high of Rs 6,717.5, underscoring a sustained period of weakness amid broader market volatility.

A sustained decline has pushed Sanofi India Ltd to a fresh 52-week low of Rs 3402.05 on 20 Mar 2026, marking a significant 49.4% drop from its peak of Rs 6717.5 over the past year. This downturn contrasts sharply with the broader market, where the Sensex has gained 1.09% today and remains only 4.79% above its own 52-week low.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sanofi India Ltd’s share price has declined to a new 52-week low, closing just 0.06% above the lowest price of Rs 3,415.8. This marks a significant downturn for the pharmaceutical company, reflecting ongoing challenges in its financial performance and market positioning over the past year.

Sanofi India Ltd’s stock price declined to a fresh 52-week low of Rs.3420 on 16 Mar 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have been under pressure, reflecting a combination of subdued financial performance and broader market weakness.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3585.65 on 13 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has now recorded losses for 11 consecutive trading sessions, shedding 13.36% during this period, reflecting persistent pressures within the Pharmaceuticals & Biotechnology sector.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3587.85 on 12 Mar 2026, marking a significant milestone in a sustained downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a combination of subdued financial results and extended negative momentum.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3650.1 today, marking a continuation of a downward trajectory that has seen the stock lose over 11.6% in the past nine trading sessions. This latest low reflects ongoing pressures on the pharmaceutical company’s market performance amid broader sector and market headwinds.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3655.65 on 9 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and broader market indices, reflecting a combination of subdued financial results and extended negative returns over the past year.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into its performance and outlook.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3796 today, marking a significant drop amid a broader market environment where the Sensex is trading lower. The stock’s recent performance reflects a continuation of downward trends both in the short and long term, with key financial indicators signalling subdued growth and profitability pressures.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3804.2 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting a combination of subdued financial results and longer-term growth concerns.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3806.05 on 4 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has been under pressure, reflecting a combination of subdued financial performance and broader market dynamics.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3806.05 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has now recorded a four-day consecutive fall, accumulating a loss of 7.63% over this period, reflecting persistent pressures on its market valuation.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3848 on 2 Mar 2026, marking a significant drop amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Sanofi India Ltd has seen a marked shift in its valuation parameters, moving from a fair to a very attractive rating despite ongoing sector headwinds and a challenging market environment. With a current price of ₹3,964, down 1.26% on the day, the pharmaceutical company’s price-to-earnings (P/E) ratio now stands at 26.31, significantly lower than many of its peers, signalling a potential value opportunity for investors.